Skip to Main Content

Sage Therapeutics said Monday that U.S. regulators accepted a marketing application for its rapid-acting antidepressant and granted it priority review with a decision date set for early August.

The Food and Drug Administration will assess the efficacy and safety of the Sage drug, a once-daily pill called zuranolone, for the treatment of people with major depressive disorder and postpartum depression.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment